Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | PRKCA | P17252 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | PTAFR | P25105 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triacetin SCHEMBL8664971 | 0.93 | PRKCA (0.63) | ALDH1A1PRKCALMNA | |
| SCHEMBL8435468 | 0.92 | ADRA1D (0.55) | ALDH1A1PRKCALMNAADRA1DPTAFR | |
| Triacetin SCHEMBL17821531 | 0.92 | PRKCA (0.55) | ALDH1A1PRKCALMNAADRA1DPTAFR | |
| SCHEMBL8438758 | 0.92 | ADRA1D (0.55) | ALDH1A1PRKCALMNAADRA1DPTAFR | |
| SCHEMBL10894210 | 0.92 | ADRA1D (0.55) | ALDH1A1PRKCALMNAADRA1DPTAFR | |
| SCHEMBL10824976 | 0.92 | ADRA1D (0.55) | ALDH1A1PRKCALMNAADRA1DPTAFR | |
| Triacetin SCHEMBL9300248 | 0.89 | PRKCA (0.69) | ALDH1A1PRKCALMNA | |
| Cetyl Alcohol SCHEMBL8600510 | 0.86 | PRKCA (0.60) | ALDH1A1PRKCALMNATSHR | |
| Cetostearyl Alcohol SCHEMBL27687492 | 0.86 | PRKCA (0.60) | ALDH1A1PRKCALMNATSHR | |
| Triacetin SCHEMBL4949915 | 0.85 | ALDH1A1 (0.48) | ALDH1A1PRKCALMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2687093-B1 | Local topical administration formulations containing indoxacarb | FMC CORP (US) | 2020-07-22 | — | — | EP | disclosed |
| US-9968617-B2 | Local topical administration formulations containing indoxacarb | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2018-05-15 | — | — | US | disclosed |
| EP-2066179-B1 | FORMULATIONS CONTAINING INDOXACARB FOR LOCAL TOPICAL ADMINISTRATION | DU PONT (US) | 2016-06-22 | — | — | EP | disclosed |
| US-20160008370-A1 | LOCAL TOPICAL ADMINISTRATION FORMULATIONS CONTAINING INDOXACARB | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2016-01-14 | — | — | US | disclosed |
| EP-2687093-A1 | Local topical administration formulations containing indoxacarb | E. I. Du Pont de Nemours and Company (US) | 2014-01-22 | — | — | EP | disclosed |
| US-20130345210-A1 | LOCAL TOPICAL ADMINISTRATION FORMULATIONS CONTAINING INDOXACARB | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION | 2013-12-26 | — | — | US | disclosed |
| US-8475818-B2 | Local topical administration formulations containing indoxacarb | E. I. DE PONT DE NEMOURS AND COMPANY (US) | 2013-07-02 | — | — | US | disclosed |
| US-20100099668-A1 | LOCAL TOPICAL ADMINISTRATION FORMULATIONS CONTAINING INDOXACARB | FMC CORPORATION | 2010-04-22 | — | — | US | disclosed |
| EP-2066179-A2 | LOCAL TOPICAL ADMINISTRATION FORMULATIONS CONTAINING INDOXACARB | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008030385-A2 | LOCAL TOPICAL ADMINISTRATION FORMULATIONS CONTAINING INDOXACARB | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345210-A1 | LOCAL TOPICAL ADMINISTRATION FORMULATIONS CONTAINING INDOXACARB | IDO1, MMP1, IDO2 | ALDH1A1 782/4885PRKCA 3625/4885LMNA 3923/4885 |
| US-20100099668-A1 | LOCAL TOPICAL ADMINISTRATION FORMULATIONS CONTAINING INDOXACARB | IDO1, MMP1, IDO2 | ALDH1A1 782/4885PRKCA 3625/4885LMNA 3923/4885 |
| US-20160008370-A1 | LOCAL TOPICAL ADMINISTRATION FORMULATIONS CONTAINING INDOXACARB | IDO1, MMP1, IDO2 | ALDH1A1 782/4885PRKCA 3625/4885LMNA 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.